Incretin Atlas › Trials › SUPER 2 (NCT04998032), phase 3 stage
SUPER 2 (NCT04998032), phase 3 stage
Efsubaglutide alfa (supaglutide) · t2d
Design
- Molecule(s)
- Efsubaglutide alfa (supaglutide)
- Population
- t2d
- Official title
- A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment(SUPER-2)
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Phase
- 2/3
- Registry status
- completed · 2021-10 → 2023-06
- Participants
- 620
- Duration
- 12, 24 weeks
- Registry
- NCT04998032
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 mg QW | t2d china | 24 | 171 | — | — | −1.8 vs −0.7 | — | — | 7.6 vs 4.0 | 9.9 vs 1.7 | — | — | press release |
| 1 mg QW | t2d china | 12 | 120 | — | — | −1.1 | — | — | — | — | — | — | press release |
| 3 mg QW | t2d china | 12 | 120 | — | — | −1.4 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 3 mg QW: Reported: 1.2 % discontinued for treatment-related adverse events only (not shown on the axis).
Verbatim quotes from the source (5)
- 3 mg QW · hba1c · publication
At week 24 in phase 3, HbA1c decreased by 1.80% with Efsubaglutide 3 mg versus 0.74% with placebo
- 3 mg QW · vomiting · publication
including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
- 3 mg QW · nausea · publication
including diarrhoea (21.6% vs. 3.5%), vomiting (9.9% vs. 1.7%), nausea (7.6% vs. 4.0%)
- 1 mg QW · hba1c · publication
At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
- 3 mg QW · hba1c · publication
At week 12 in phase 2b, HbA1c decreased by 1.10% with 1 mg and 1.43% with 3 mg
Primary sources
- Innogen (Yinnuo). Efsubaglutide alfa added to metformin in T2D: randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2). Nat Commun 2026 [publication]. 2026-05-08. Available from: https://www.nature.com/articles/s41467-026-72574-7
- ClinicalTrials.gov NCT04998032
How to cite this page
Medical Adviser's Group. Incretin Atlas: SUPER 2 (NCT04998032), phase 3 stage. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/super-2-phase-3-stage/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.